Free Trial
→ 9/9 on TSLA from June to January (From Wealthpin Pro) (Ad)

Azitra Q3 2023 Earnings Report

Azitra logo
$0.37 -0.04 (-10.00%)
As of 02/21/2025 04:10 PM Eastern
Earnings History

Azitra EPS Results

Actual EPS
-$4.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
$0.31 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Q3 2023
Date
11/14/2023
Time
N/A

Conference Call Resources

Azitra Earnings Headlines

Azitra Inc. issues new warrants in connection with stock sale
February 7, 2025 | msn.com
Azitra sees 3.34M shares at 27.85c in registered direct offering
February 5, 2025 | markets.businessinsider.com
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
February 23, 2025 | Wealthpin Pro (Ad)
Azitra secures $930K in registered direct offering
February 5, 2025 | msn.com
Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock
February 4, 2025 | prnewswire.com
Azitra, Inc. to Present at the BIO CEO & Investor Conference
February 3, 2025 | prnewswire.com
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles